Skip to main content

Table 3 Univariate and multivariate analysis of PCDH17 expression for overall survival in the Chinese cohort

From: Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia

Variables

Univariate analysis

Multivariate analysis

Hazard Ratio (95% CI)

P

Hazard Ratio (95% CI)

P

Full cohort

(n = 97)

(n = 97)

PCDH17 a

1.65 (1–2.72)

0.05

2.01 (1.19–2.98)

0.01

Ageb

3.07 (1.87–5.04)

< 0.0001

2.10 (1.18–3.61)

0.02

WBC countc

3.14 (1.92–5.14)

< 0.0001

2.06 (1.16–3.64)

0.01

Cytogenetic riskd

2.04 (1.49–2.78)

< 0.0001

1.60 (1.05–2.43)

0.03

FLT3-ITDe

0.80 (0.36–1.77)

0.58

–

–

NPM1 f

0.97 (0.39–2.43)

0.95

–

–

CEBPA f

1.18 (0.53–2.62)

0.69

–

–

DNMT3A f

1.66 (0.71–3.89)

0.24

–

–

IDH2 f

6.13 (0.8–47)

0.08

5.35 (0.63–45.16)

0.12

NRAS f

1.18 (0.37–3.81)

0.78

–

–

KRAS f

8.80 (2.53–30.55)

< 0.001

5.16 (1.13–23.59)

0.03

U2AF1 f

14.43 (1.81–115.4)

0.01

4.99 (0.37–67.94)

0.23

SRSF2 f

3.28 (0.78–13.85)

0.11

0.95 (0.12–7.46)

0.96

SETBP1 f

0.82 (0.11–5.96)

0.85

–

–

KIT f

0.64 (0.16–2.64)

0.54

–

–

CN-AML

(n = 36)

(n = 36)

PCDH17 a

2.58 (1.02–6.52)

0.04

2.95 (1.04–8.32)

0.04

Ageb

1.39 (0.61–3.14)

0.43

–

–

WBC countc

3.05 (1.34–6.93)

0.008

3.26 (1.35–7.87)

0.009

FLT3-ITDe

0.48 (0.14–1.63)

0.24

–

–

NPM1 f

0.50 (0.15–1.69)

0.27

–

–

CEBPA f

1.19 (0.40–3.50)

0.76

–

–

DNMT3A f

1.25 (0.42–3.68)

0.69

–

–

IDH2 f

6.37 (0.76–53.48)

0.09

13.30 (1.23–143.32)

0.03

NRAS f

3.55 (0.45–27.94)

0.23

–

–

KRAS f

6.46 (1.37–30.46)

0.02

9.17 (1.72–48.86)

0.009

SETBP1 f

6.37 (0.76–53.48)

0.09

4.52 (0.48–42.10)

0.19

  1. Hazard ratio > 1 or Hazard ratio < 1 indicate a higher or lower risk. Only variables with a univariable P ≤ 0.20 were included in the multivariable models. Mutations such as IDH1 and TP53 were either not analyzed or detected in our cohort, thus they were not included in this analysis
  2. CI confidence interval, WBC white blood cells, CN-AML cytogenetically normal AML, ITD internal tandem duplication
  3. aLow vs high expression
  4. b > 60 vs ≤ 60 years
  5. c ≥ 30 vs < 30 × 109/L
  6. dAdverse vs intermediate vs favorable
  7. ePresent vs absent
  8. fMutated vs wild type
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us